Abstract 328P
Background
Breast cancer (BC) is the most common malignancy in female patients (pts) with Li-Fraumeni Syndrome (LFS). These pts are at increased risk of other malignancies, including radiotherapy-induced malignancies (RIM) that are those occurring in a previously irradiated field. We aimed to evaluate the frequency of RIM and other oncologic outcomes of LFS pts with eBC.
Methods
We evaluated pts with a germline pathogenic/likely pathogenic variant of TP53 (LFS) diagnosed with eBC and followed by the Hereditary Cancer Team of a single cancer center between Dec/99 and Apr/23. The primary endpoint was the frequency of RIM among pts treated with adjuvant RT.
Results
Forty-nine pts were evaluated. Median age was 39 years (range 21 - 62); 79% were ER-positive; 35% HER2-positive; 35% stage I and 27% stage II; and 71% had TP53 R337H variant. Most pts (87%) were unaware of the LFS at the time of BC treatment. Regarding treatment, 62% underwent a mastectomy, 66% (neo)adjuvant chemotherapy, and 62% RT. The use of RT was more common after conservative surgery as expected (87% vs 46% with mastectomy, P=0.010). Oncologic outcomes are summarized in the table. Among 30 pts treated with RT, 4 (13.8%) developed RIM in the irradiated field (3 soft tissue malignancies and 1 BC). The occurrence of RIM was not influenced by RT dose (≤ 40.8 or > 40.8), but was influenced by the type of RT. RIM was observed in 100% with 2D RT (n=2/2), 100% (n=1/1) with volumetric modulated arc therapy (VMAT), 6% (n=1/16) with 3D RT, and 0% with intensity-modulated RT (n=0/1) (P=0.007). Table: 328P
Radiotherapy (n=30) | No radiotherapy (n=18) | P | |
Local recurrence | 2 (6.7%) | 1 (5.6%) | 1.000 |
Distant recurrence | 5 (16.7%) | 1 (5.6%) | 0.388 |
Contralateral BC | 5 (16.7%) | 2 (11.1%) | 0.696 |
Second neoplasia | 15 (50%) | 5 (27.8%) | 0.226 |
RIM | 4 (13.8%) | - | - |
Conclusions
Our study confirms an alarming rate of RIM after adjuvant RT, highlighting the need for a careful risk-benefit evaluation for the indication of RT, which should be preferentially avoided if possible. Despite the small numbers in each subgroup, the risk of RIM seemed to be influenced by the RT technique, with higher rates with 2D RT and VMAT. Early TP53 testing is crucial to guide the BC treatment plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Petry: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Novartis. R. Colombo Bonadio: Financial Interests, Personal, Invited Speaker: AstraZeneca, Daiichi Sankyo, Gilead, Nestle Health, Zodiac; Financial Interests, Personal, Expert Testimony: Ache; Financial Interests, Institutional, Research Funding: Novartis, AstraZeneca. L. Testa: Financial Interests, Personal, Advisory Board: AstraZeneca, Lilly, Novartis, Daiichi Sankyo, MSD; Financial Interests, Institutional, Research Funding: Novartis; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Daiichi Sankyo, MSD, Lilly, Zodiac, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
263P - Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Presenter: Layal Rached
Session: Poster session 02
264P - Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Presenter: Sheyda Abdullaeva
Session: Poster session 02
265P - Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
Presenter: Yijun Li
Session: Poster session 02
266P - Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Francesca Schipilliti
Session: Poster session 02
267P - Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Presenter: Fabio Canino
Session: Poster session 02
268P - Evaluating the efficacy of adjuvant capecitabine in triple-negative breast cancer patients with residual disease: A real-world evidence study
Presenter: Min Jeong Kim
Session: Poster session 02
269P - Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight
Presenter: Eda Caliskan Yildirim
Session: Poster session 02
270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Presenter: Seung Eun Lee
Session: Poster session 02
271P - First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Presenter: Sara Nizzero
Session: Poster session 02